It's been a sad week for ReposiTrak, Inc. (NYSE:TRAK), who've watched their investment drop 14% to US$6.14 in the week since the company reported its first-quarter result. ReposiTrak beat revenue forecasts by a solid 16% to hit US$5.8m. Statutory earnings per share came in at US$0.08, in line with expectations. Following the result, the analyst has updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analyst has changed their earnings models, following these results.
After the latest results, the sole analyst covering ReposiTrak are now predicting revenues of US$26.3m in 2027. If met, this would reflect a meaningful 14% improvement in revenue compared to the last 12 months. Statutory per share are forecast to be US$0.39, approximately in line with the last 12 months. Yet prior to the latest earnings, the analyst had been anticipated revenues of US$25.5m and earnings per share (EPS) of US$0.43 in 2027. Overall it looks as though the analyst was a bit mixed on the latest results. Although there was a a meaningful to revenue, the consensus also made a small dip in its earnings per share forecasts.
View our latest analysis for ReposiTrak
The analyst also cut ReposiTrak's price target 45% to US$16.00, implying that lower forecast earnings are expected to have a more negative impact than can be offset by the increase in revenue.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The analyst is definitely expecting ReposiTrak's growth to accelerate, with the forecast 19% annualised growth to the end of 2027 ranking favourably alongside historical growth of 5.4% per annum over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 17% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that ReposiTrak is expected to grow at about the same rate as the wider industry.
The biggest concern is that the analyst reduced their earnings per share estimates, suggesting business headwinds could lay ahead for ReposiTrak. There was also an upgrade to revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. Furthermore, the analyst also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At least one analyst has provided forecasts out to 2028, which can be seen for free on our platform here.
Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.